Skip to main content
XTL Biopharmaceuticals Ltd. logo

XTL Biopharmaceuticals Ltd. — Investor Relations & Filings

Ticker · XTLB ISIN · IL0010854979 LEI · 529900NDDXEAPTUTXP41 TA Manufacturing
Open in API
Filings indexed 1,223 across all filing types
Latest filing 2022-01-26 AGM Information
Country IL Israel
Listing TA XTLB

About XTL Biopharmaceuticals Ltd.

https://www.xtlbio.com

XTL Biopharmaceuticals Ltd. is a clinical-stage biopharmaceutical company focused on the acquisition and development of pharmaceutical products to address unmet clinical needs. The company's primary therapeutic area of interest is autoimmune diseases. Its development pipeline has included proprietary drug candidates for conditions such as Systemic Lupus Erythematosus (SLE).

Recent filings

Filing Released Lang Actions
results of the Annual General Meeting of shareholders of the Company, Wednesday, January 26, 2022
AGM Information Classification · 98% confidence The document explicitly states, "Attached hereto is a report on *AGM Results*" and references a PDF file named '6k_xtlbiopharEDGAR1_bannerless_isa.pdf'. The presence of 'AGM Results' strongly indicates information pertaining to the Annual General Meeting. Since this document is an announcement stating that the results report is attached, and given its short length (1860 chars), it fits the criteria for a Report Publication Announcement (RPA) or, more specifically, a filing related to AGM results. Given the specific category 'AGM-R' for AGM materials, and the nature of the attachment being the results, AGM-R is the most precise classification, although RPA is also plausible if the focus is purely on the announcement mechanism. However, since the content *is* the AGM result announcement, AGM-R is preferred over the generic RPA.
2022-01-26 English
FORM 6-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, XTL Biopharmaceuticals Ltd. It announces the results of the Annual General Meeting (AGM) held on January 26, 2022, including the appointment of auditors and re-election of board members. The content focuses on the AGM resolutions and does not contain detailed financial statements or comprehensive annual report data. The document length is 3830 characters, which is relatively short and primarily serves as an announcement of AGM results rather than the full AGM materials or annual report. Therefore, the document fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it officially reports the voting outcomes from the AGM.
2022-01-26 English
A meeting which was called for 19/01/2022 was postponed to 26.1.22
Director's Dealing Classification · 98% confidence The document text consists of multiple declarations titled 'Declaration of Director's Qualification' under Section 224(b) of the Israeli Companies' Law. These declarations detail the qualifications, experience, and shareholdings of individuals (Alexander Rabinovich, Dr. Jonathan Schapiro, Shlomo Shalev, Doron Turgeman) seeking or holding positions as directors in the company. This type of filing relates directly to the composition and qualifications of the Board of Directors and senior management. This aligns best with the 'Board/Management Information' category (MANG), which covers announcements of changes in the company's board of directors or senior management, as this document confirms their eligibility to serve.
2022-01-19 English
A meeting which was called for 19/01/2022 was postponed to 26.1.22
AGM Information Classification · 95% confidence The document is explicitly titled "Form 6-K, Report of Foreign Private Issuer" filed with the SEC for the month of January 2022. Form 6-K is a general reporting requirement for foreign private issuers, often used to disseminate material information to the public in their home country or to satisfy continuous disclosure obligations. The content announces the postponement of the annual shareholders' meeting. While it relates to an AGM, the primary filing mechanism here is the Form 6-K, which is a broad regulatory filing. Since there is no specific code for Form 6-K, and the content is a material announcement that doesn't fit perfectly into ER, IR, or AGM-R (which is usually the presentation material), the most appropriate general regulatory category is RNS (Regulatory Filings), which serves as a fallback for miscellaneous SEC filings that aren't 10-K, 10-Q, or proxy statements. Given the document's nature as a formal SEC filing disseminating material news, RNS is the best fit among the provided options.
2022-01-19 English
A meeting which was called for 19/01/2022 was postponed to 26.1.22
AGM Information Classification · 98% confidence The document explicitly states it is an "Immediate Report of Meeting" and details the "postponement of meeting" from 19/01/2022 to 26/01/2022. The agenda items include discussing the auditor's report and appointing auditors, which are typical items for an Annual General Meeting (AGM). Furthermore, item 3, 4, 5, and 6 explicitly mention re-electing directors for a term expiring at the "next annual general meeting of shareholders." This content strongly indicates materials related to the AGM process, specifically the notice/postponement of the meeting itself, which aligns best with the AGM Information (AGM-R) category, as it details the meeting logistics and agenda items.
2022-01-19 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, XTL Biopharmaceuticals Ltd., with the SEC. It announces the postponement of the annual shareholders' meeting due to lack of quorum and provides the rescheduled date. The document is short (2996 characters) and primarily serves as an announcement rather than a detailed report. It does not contain financial statements or substantive financial data. It is not a full annual report, interim report, or earnings release. It is also not a proxy solicitation or voting results announcement. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a corporate event (meeting postponement) without detailed financial or governance data.
2022-01-19 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.